Semaglutide and cardiovascular benefits: the SELECT trial

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

The SELECT trial showed semaglutide 2.4mg weekly reduced major adverse cardiovascular events (MACE) by 20% in patients with overweight/obesity and established CVD. This cardioprotective effect is independent of weight loss, making semaglutide a key agent for comprehensive cardiovascular risk reduction.

The landmark SELECT trial demonstrated that semaglutide 2.4mg weekly significantly reduced the risk of major adverse cardiovascular events (MACE) by 20% in patients with overweight or obesity and established cardiovascular disease [1].

This finding is a game-changer, extending semaglutide's benefits far beyond just weight loss and glycemic control. We're talking about a direct impact on hard cardiovascular outcomes. You'll find that this reduction in MACE was observed independently of the degree of weight loss, suggesting additional cardioprotective mechanisms. Dr. A. Michael Lincoff's 2023 publication of the SELECT trial results in the New England Journal of Medicine provides the definitive data. Don't view semaglutide as just a weight loss drug; it's a cardiovascular protector.

Mechanisms of Cardioprotection

Beyond weight loss, semaglutide"s cardioprotective effects are thought to involve improvements in blood pressure, lipid profiles, inflammation, and endothelial function. It"s a multifaceted action that targets several pathways contributing to cardiovascular disease. The SELECT trial"s robust findings underscore the importance of GLP-1 agonists in comprehensive cardiovascular risk reduction. You can"t ignore these.

Semaglutide vs. SGLT2 Inhibitors: Cardioprotective Synergy

While SGLT2 inhibitors also offer significant cardiovascular benefits, particularly for heart failure and kidney disease, semaglutide\\\\"s primary cardiovascular benefit in the SELECT trial was MACE reduction in patients with established CVD and obesity. These drug classes have complementary mechanisms and can be used synergistically. For instance, a patient with type 2 diabetes, obesity, and heart failure might benefit from both. It\\\\"s not an either-or situation; it\\\\"s about maximizing benefits. You\\\\"ll see that combining therapies often yields superior outcomes.

Addressing the Nuance

The SELECT trial\\\\\"s finding of MACE reduction independent of weight loss is a significant nuance, suggesting direct cardioprotective effects beyond metabolic improvements. However, the trial population had established CVD, so these findings may not directly extrapolate to primary prevention. The optimal integration of semaglutide with other cardioprotective agents (e.g., statins, SGLT2 inhibitors) requires individualized assessment and ongoing research to define synergistic benefits.

Clinical Takeaway

For patients with established cardiovascular disease and obesity, semaglutide (2.4mg weekly) is a critical intervention to reduce MACE, independent of its weight-loss effects. Integrate semaglutide into a comprehensive cardiovascular risk reduction strategy alongside statins, antiplatelets, and blood pressure medications. Counsel patients on the dual benefits of weight loss and direct cardioprotection. Consider early initiation in eligible patients.

Further research continues to refine our understanding of semaglutide's multifaceted effects and optimal patient management strategies. Clinicians should stay abreast of emerging data to provide the most effective and personalized care.